Clinical Report: Evaluation of Cutaneous Immune-Related Adverse Events

Overview

This comprehensive review and meta-analysis highlights the spectrum of dermatologic immune-related adverse events (d-irAEs) in melanoma patients undergoing immunotherapy. It emphasizes the need for continuous dermatological surveillance and a multidisciplinary approach for effective management.

Background

The increasing incidence of melanoma, particularly among older populations, necessitates effective treatment strategies. Immune checkpoint inhibitors (ICIs) have revolutionized melanoma therapy, but they are associated with a range of d-irAEs that can impact patient quality of life and treatment adherence. Understanding and managing these adverse events is crucial for optimizing patient outcomes.

Data Highlights

No specific numerical data provided in the article.

Key Findings

• d-irAEs can range from mild to life-threatening, requiring careful monitoring.
• Real-world reports of mild-to-moderate d-irAEs are significantly underreported.
• A multidisciplinary approach is essential for the early detection and management of skin toxicities.
• Continuous dermatological assessment during immunotherapy is necessary to mitigate adverse effects.
• Neoadjuvant immunotherapy shows superior clinical outcomes compared to adjuvant therapy alone.

Clinical Implications

Detail specific strategies for collaboration between dermatologists and oncologists.

Conclusion

The review underscores the importance of recognizing and managing d-irAEs in melanoma patients treated with immunotherapy. Enhanced reporting and a structured management approach can improve patient outcomes.

Related Resources & Content

1. The ASCO Post, January 2020 -- Immune-Related Adverse Events and Recurrence-Free Survival With Adjuvant Immunotherapy vs Placebo in Stage III Melanoma
2. Blood Cancer Journal (Nature Portfolio) -- Skin-related adverse effects associated with CAR T-cell therapy in blood cancers
3. The ASCO Post, October 15, 2013 -- How to Recognize and Manage Ipilimumab-Induced Dermatologic Adverse Events
4. ASCO’s Management of Immune-related Adverse Effects Guideline is Now Open for Public Comment - Guideline Central
5. Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial | Nature Medicine
6. The ASCO Post — How to Recognize and Manage Ipilimumab-Induced Dermatologic Adverse Events
7. ASCO’s Management of Immune-related Adverse Effects Guideline is Now Open for Public Comment - Guideline Central
8. Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial | Nature Medicine
9. Frontiers | Cutaneous adverse events associated with the efficacy and benefit of immune checkpoint inhibitors: a systematic review and meta-analysis